CPRC
EW icon

Consolidated Portfolio Review Corp’s Edwards Lifesciences EW Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,780
Closed -$216K – 152
2025
Q3 		$216K Buy
+2,780
New +$217K 0.03% 427

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Consolidated Portfolio Review Corp's EW Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 2,780 shares — an estimated $216K sold.

Consolidated Portfolio Review Corp first reported a position in EW in Q3 2025 and held it in 1 quarter. The position peaked at $216K in Q3 2025. 1,313 funds tracked by Wall St. Rank hold EW as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 2,780 Edwards Lifesciences shares in Q4 2025, an estimated $216K.
  • Consolidated Portfolio Review Corp first reported a position in Edwards Lifesciences in Q3 2025 and held it in 1 quarter.
  • Consolidated Portfolio Review Corp's Edwards Lifesciences position peaked at $216K in Q3 2025.
  • 1,313 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.